Tiziana Life Sciences
London · Founded 1998
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:TLSA
- Website: tizianalifesciences.com
- Phone: +44 (0) 207 495 2379
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/tiziana-life-sciences-82733 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.